Market Snapshot
  • U.S.
  • Europe
  • Asia
Ticker Volume Price Price Delta
DJIA 16,424.85 162.29 1.00%
S&P 500 1,862.31 19.33 1.05%
NASDAQ 4,086.22 52.06 1.29%
Ticker Volume Price Price Delta
STOXX 50 3,135.83 -3.43 -0.11%
FTSE 100 6,576.15 -8.02 -0.12%
DAX 9,315.19 -2.63 -0.03%
Ticker Volume Price Price Delta
NIKKEI 14,417.53 -0.15 -0.00%
TOPIX 1,166.59 0.04 0.00%
HANG SENG 22,725.13 29.12 0.13%

Turning complex hip revisions into efficient, reproducible surgeries with the new REDAPT™ Revision Femoral System from Smith &



Turning complex hip revisions into efficient, reproducible surgeries with the
           new REDAPT™ Revision Femoral System from Smith & Nephew

PR Newswire

LONDON, Nov. 15, 2012

LONDON, Nov. 15, 2012 /PRNewswire/ -- Smith & Nephew (LSE: SN, NYSE: SNN), the
global medical technology business, announces the launch of their new REDAPT™
Revision Femoral System. Designed to bring the concept of personalized patient
treatments to the revision hip market, the new system's versatility allows
surgeons to effectively recreate a patient's unique functionality while
quickly and easily addressing issues such as poor bone quality and
proximal/distal mismatch.

"With other revision systems, the main goal is simply to provide a patient
with a stable joint," says Dr. Reid Brown of Louisville Bone and Joint
Specialists in Kentucky. "REDAPT changes these outcome expectations to include
the type of functional standards typically associated with primary total hip
replacements. And, it does so with streamlined, reproducible instrumentation
and a shorter learning curve."  

Unlike many of the other revision systems, the REDAPT System's unique and
efficient surgical technique allows a surgeon to prepare the femoral canal and
complete full hip range of motion tests completely off its
instrumentation. This gives the surgeon an ability to determine precise
implant position for optimal stability before introducing a solid stem,
predictably within the femoral canal. The advantage of the solid, monolithic
stem is that it means a surgeon can avoid placing a modular, mid-stem junction
at a critical, high stress location for the stem.

Also contributing to the system's overall versatility are its two available
stem styles – a Proximally Fluted (PF), or sleeveless, stem for use when
proximal bone defects are limited, and a Modular Sleeved (MS) stem for cases
where proximal and distal bone defects are more prevalent. During pre-launch
evaluation, both stem styles received very positive reviews from surgeons. In
particular, surgeons appreciated the REDAPT System's ability to provide
reproducible stem positioning due to its taper design, precision
instrumentation and use of Smith & Nephew's proprietary ROCKTITE™ Flutes,
which deliver "rock-solid" distal fixation in all defect types.

"Modularity is critical in today's increasing complicated total hip revision
surgery," says Dr. Mathias Bostrom of the Hospital for Special Surgery in New
York. "As the revision becomes more complex, modularity is what allows me to
restore center of rotation, return leg length and provide a stable hip for my
patients."

With the REDAPT System, surgeons are also able to "fine tune" the joint for
leg length, offset, and version through the system's five available modular
neck options; four of which can be inverted. When combined, the system's
multiple head lengths and neck options mean that the REDAPT system offers
surgeons 54 head center options. Each neck is compatible with Smith & Nephew
cobalt chrome, ceramic, and OXINIUM™ heads.

"Our goal was to create one system that surgeons could rely on for any type of
revision from mild to severe," says Gaurav Agarwal, DSVP and General Manager
for Smith & Nephew's Advanced Surgical Devices Division. "Not only did we
achieve our goal, we created a system that's revolutionary in its versatility,
its simplicity and its reproducibility."

About Smith & Nephew

Smith & Nephew is a global medical technology business dedicated to helping
improve people's lives.  With leadership positions in Orthopaedic
Reconstruction, Advanced Wound Management, Sports Medicine and Trauma, Smith &
Nephew has almost 11,000 employees and a presence in more than 90 countries.
Annual sales in 2011 were nearly $4.3 billion.  Smith & Nephew is a member of
the FTSE100 (LSE: SN, NYSE: SNN).

Forward-looking Statements   
This document may contain forward-looking statements that may or may not prove
accurate. For example, statements regarding expected revenue growth and
trading margins, market trends and our product pipeline are forward-looking
statements. Phrases such as "aim", "plan", "intend", "anticipate",
"well-placed", "believe", "estimate", "expect", "target", "consider" and
similar expressions are generally intended to identify forward-looking
statements. Forward-looking statements involve known and unknown risks,
uncertainties and other important factors that could cause actual results to
differ materially from what is expressed or implied by the statements. For
Smith & Nephew, these factors include: economic and financial conditions in
the markets we serve, especially those affecting health care providers, payors
and customers; price levels for established and innovative medical devices;
developments in medical technology; regulatory approvals, reimbursement
decisions or other government actions; product defects or recalls; litigation
relating to patent or other claims; legal compliance risks and related
investigative, remedial or enforcement actions; strategic actions, including
acquisitions and dispositions, our success in integrating acquired businesses,
and disruption that may result from changes we make in our business plans or
organisation to adapt to market developments; and numerous other matters that
affect us or our markets, including those of a political, economic, business
or competitive nature. Please refer to the documents that Smith & Nephew has
filed with the U.S. Securities and Exchange Commission under the U.S.
Securities Exchange Act of 1934, as amended, including Smith & Nephew's most
recent annual report on Form 20-F, for a discussion of certain of these
factors.

Any forward-looking statement is based on information available to Smith &
Nephew as of the date of the statement. All written or oral forward-looking
statements attributable to Smith & Nephew are qualified by this caution. Smith
& Nephew does not undertake any obligation to update or revise any
forward-looking statement to reflect any change in circumstances or in Smith &
Nephew's expectations.

Trademark of Smith & Nephew.  Registered US Patent and Trademark Office.

SOURCE Smith & Nephew

Website: http://www.smith-nephew.com
Contact: Media: Brad Merrick, Smith & Nephew, +1-901-399-1089,
Brad.merrick@smith-nephew.com; or Investor/Analyst: Phil Cowdy, Smith &
Nephew, 44 (0)20 7401 7646, Phil.Cowdy@smith-nephew.com
Sponsored Links
Advertisement
Advertisements
Sponsored Links
Advertisement